Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 12/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156482 | 1.00 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 | |
| SCHEMBL3088236 | 0.84 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13156474 | 0.84 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13156517 | 0.84 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3106294 | 0.84 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4309782 | 0.79 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4162795 | 0.79 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4159220 | 0.79 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL15962708 | 0.74 | TAS1R3 (0.72) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 | |
| SCHEMBL15956601 | 0.74 | TAS1R3 (0.72) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | TAS1R3 4604/4885TAS1R1 4471/4885TAS1R2 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.